NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

ASCO publishes guideline on treating pregnant women with blood cancers

A guideline from the American Society of Clinical Oncology offers clear, evidence-based direction for treating blood cancers during pregnancy and shows that many patients can safely receive timely cancer care without compromising fetal health.

December 19, 2025

Vol.51 No.46

Clinical Roundup

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

A study led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found the drug pirtobrutinib worked as well as another drug, ibrutinib, in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and people in the study responded better with pirtobrutinib.

December 19, 2025

Vol.51 No.46

Drugs & Targets

EC approval of Minjuvi in relapsed or refractory follicular lymphoma

The European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grade 1-3a) after at least one line of systemic therapy.

December 19, 2025

Vol.51 No.46

In Brief

Renuka Iyer named chief medical officer for NCCN

Renuka Iyer was appointed chief medical officer for the National Comprehensive Cancer Network—an alliance of leading cancer centers that publishes free evidence-based, expert consensus-driven guidelines for cancer prevention and care.

December 12, 2025

Vol.51 No.45

Drugs & Targets

EC approves expanded use of CAR T-cell therapy Breyanzi for r/r mantle cell lymphoma

The European Commission has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.

December 05, 2025

Vol.51 No.44